Oral Adelmidrol Administration Up-Regulates Palmitoylethanolamide Production in Mice Colon and Duodenum through a PPAR-γ Independent Action
Laboratory studyOther animalsWith adelmidrol (a PEA analogue, tested alone)
This study tested palmitoylethanolamide together with adelmidrol (a PEA analogue, tested alone). Its results cannot be assigned to palmitoylethanolamide alone. More combination studies.
- Design
- Laboratory study
- Subjects
- Mice given 21 days of oral treatment, with and without a PPAR-gamma inhibitor
- Dose used in the study
- Adelmidrol 1 and 10 mg/kg orally for 21 days; PPAR-gamma inhibitor 1 mg/kg
- Duration
- 21 days
- What was measured
- Endogenous palmitoylethanolamide levels in duodenum and colon (by HPLC-MS) and expression of palmitoylethanolamide-related metabolic enzymes (western blot and RT-PCR), with and without a PPAR-gamma antagonist
What the authors reported
Adelmidrol increased palmitoylethanolamide levels in the duodenum and colon in a dose- and time-dependent manner and increased expression of the enzymatic machinery for palmitoylethanolamide metabolism. A selective irreversible PPAR-gamma antagonist did not change intestinal palmitoylethanolamide levels or enzyme expression/transcription after adelmidrol, so the effect was independent of PPAR-gamma.
Limits of this study
A mouse study of a proposed entourage mechanism; it cannot show effect in people or in disease models. The authors declare no conflict of interest.
Source
PubMed 35629962 · doi:10.3390/metabo12050457
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.